Sage has a robust portfolio of fully-owned, novel drug candidates being developed for disorders of the brain and central nervous system (CNS). Our proprietary compounds target the GABA and NMDA receptor systems. Dysfunction in these systems is known to be at the core of numerous disorders.
Translational data drives efficiency in our drug development approach
We use a translational research strategy to explore the activity of our compounds, and their potential in the treatment of disorders of the brain and central nervous system. Our distinct approach begins by conducting small clinical studies to evaluate activity and methodology. We measure biomarkers—from electrical activity to functional brain imaging—to gain insight into how brain cells are communicating with each other. These tools help us understand targets in context – and then inform the design of later stage clinical trials in well-defined patient populations.
Our lead program, a proprietary intravenous formulation of brexanolone, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. We are developing next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders.